文献速递神经肿瘤

术中技术进步与精准胶质瘤手术的新前沿

Intraoperative technological advances and new frontiers in precision glioma surgery.
PubMed 文献 · J Neurooncol · 2026-07-04

本文综述胶质瘤手术中用于优化肿瘤描绘与安全切除以及增强局部治疗递送的术中技术。清醒开颅与直接电刺激仍是保留功能区与皮层下传导束的金标准;5-ALA与荧光素联合使用可获得比单药更高的切除范围;术中MRI联合5-ALA提供当前最大化安全切除的最强平台。新兴组织表征工具与血脑屏障穿透治疗手段共同构成精准胶质瘤手术的分阶段术中工作流。

要点

  • 清醒开颅与直接电刺激是保留功能区并提高全切率的金标准。
  • 5-ALA与荧光素联合使用比单药获得更大切除范围。
  • 术中MRI联合5-ALA是当前最大化安全切除的最强平台。

核心结论

  • 将互补的术中技术整合为分阶段工作流(术前规划、实时切除引导、术中边缘与组织评估、切除后局部治疗递送)构成精准胶质瘤手术的新范式。

研究设计与样本

  • 本文为综合性叙述性综述,围绕优化肿瘤描绘与安全切除以及增强局部治疗递送两个临床需求组织已确立与新兴的术中技术。

主要发现

  • 清醒开颅与直接电刺激持续减少术后神经功能缺损并提高大体全切除率。
  • 5-ALA与荧光素联合使用比任一单药获得更大切除范围。
  • 术中MRI补偿进行性脑移位,与5-ALA联合提供当前最大化安全切除的最强平台。
  • 刺激拉曼组织学、共聚焦激光显微内镜及FastGlioma、DeepGlioma等AI平台可快速术中分子诊断,无需等待常规冰冻病理。
  • 低频聚焦超声与对流增强递送绕过血脑屏障实现高局部药物浓度,血管内动脉灌注可跨肿瘤血管区域靶向递送。

临床怎么用

  • 清醒开颅与直接电刺激用于保留功能区与皮层下传导束并提高全切率。
  • 5-ALA与荧光素联合用于增强肿瘤边缘实时可视化以获得更大切除范围。
  • 术中MRI联合5-ALA用于补偿脑移位并最大化安全切除。
  • 低频聚焦超声、对流增强递送及血管内动脉灌注用于绕过血脑屏障实现局部治疗递送。

局限性

  • 需前瞻性验证组合策略、标准化技术整合方案并严格评估神经功能与肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse gliomas remain among the most surgically challenging tumors, characterized by their infiltrative nature, proximity to eloquent brain structures, and the formidable barrier posed by the BBB to systemic therapeutic delivery. Maximizing extent of resection (EOR) while preserving neurological function remains a central determinant of survival and quality of life, and the iterative integration of intraoperative technologies into surgical practice has become essential to achieving this balance. METHODS: We performed a comprehensive narrative review of established and emerging intraoperative technologies for glioma surgery, organized around two clinical imperatives: optimizing tumor delineation and safe resection, and enhancing local therapeutic delivery. RESULTS: Awake craniotomy with direct electrical stimulation remains the gold standard for preserving eloquent cortex and subcortical tracts, consistently reducing postoperative neurological deficits while increasing gross total resection rates. Fluorescence-guided surgery with 5-ALA and fluorescein enhances real-time tumor margin visualization, and their combined use achieves greater EOR than either agent alone. Intraoperative MRI compensates for progressive brain shift and, when used alongside 5-ALA, provides the strongest currently available platform for maximizing safe resection. Augmented reality navigation further enhances spatial orientation by overlaying 3D virtual anatomy directly onto the operative field. Emerging tissue characterization tools, including stimulated Raman histology, confocal laser endomicroscopy, and AI-based platforms such as FastGlioma and DeepGlioma, enable rapid intraoperative molecular diagnosis without the delays of conventional frozen section pathology. For therapeutic delivery, low-frequency focused ultrasound and convection-enhanced delivery bypass the BBB to achieve high local drug concentrations, while endovascular intra-arterial infusion enables targeted delivery across the tumor vascular territory. Photodynamic and sonodynamic therapy generate localized cytotoxic effects within the resection cavity at the time of surgery. Intraoperative brachytherapy with Cesium-131 tile implants delivers conformal radiation at the time of resection and may potentiate antitumor immunity. Laser interstitial thermal therapy combines cytoreduction with sustained BBB disruption, creating a therapeutic window for otherwise CNS-impermeant agents including checkpoint inhibitors. CONCLUSION: The deliberate integration of these complementary modalities into a phase-organized intraoperative workflow, spanning preoperative planning, real-time resection guidance, intraoperative margin and tissue assessment, and post-resection locoregional therapeutic delivery, defines the emerging paradigm of precision glioma surgery. Realizing the full potential of this framework will require prospective validation of combinatorial strategies, standardization of technology integration protocols, and rigorous evaluation of neurological and oncological outcomes.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Faraj CA, Young CC, Beckham TH, et al. Intraoperative technological advances and new frontiers in precision glioma surgery. J Neurooncol. 2026. PMID: 42400691. doi:10.1007/s11060-026-05686-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。